keyword
MENU ▼
Read by QxMD icon Read
search

Onabotulinumtoxina

keyword
https://www.readbyqxmd.com/read/29124347/the-effect-of-onabotulinumtoxina-according-to-site-of-injection-in-patients-with-overactive-bladder-a-systematic-review-and-meta-analysis
#1
Jung Ki Jo, Kyu Nam Kim, Dong Won Kim, Yong Tae Kim, Ji Yoon Kim, Ji Yeon Kim
PURPOSE: This study assessed the efficacy and safety of onabotulinumtoxinA according to injection site for treatment of overactive bladder. METHODS: A systematic literature review located randomized controlled trials of onabotulinumtoxinA treatment for neurogenic detrusor overactive bladder and idiopathic overactive bladder in adults. We searched MEDLINE, EMBASE, and the Cochrane Controlled Trials Register using the Ovid platform. Meta-analysis was based on Cochrane Review Methods...
November 9, 2017: World Journal of Urology
https://www.readbyqxmd.com/read/29067433/urinary-incontinence-in-women-a-review
#2
REVIEW
Emily S Lukacz, Yahir Santiago-Lastra, Michael E Albo, Linda Brubaker
Importance: Urinary incontinence, the involuntary loss of urine, is a common health condition that may decrease quality of life. Ten to twenty percent of women and up to 77% of women residing in nursing homes have urinary incontinence, yet only 25% seek or receive treatment. Observations: This review summarizes the evaluation and therapeutic options for women affected by urinary incontinence. The initial assessment should focus on understanding the effect of incontinence on quality of life, the patient's goals and preferences for treatment, the results of previous treatments, and the presence of concomitant conditions, such as advanced pelvic organ prolapse, that may require referral...
October 24, 2017: JAMA: the Journal of the American Medical Association
https://www.readbyqxmd.com/read/29064991/efficacy-of-incobotulinumtoxina-for-the-treatment-of-glabellar-frown-lines-in-male-subjects-post-hoc-analyses-from-randomized-double-blind-pivotal-studies
#3
RANDOMIZED CONTROLLED TRIAL
Derek H Jones, Martina Kerscher, Thorin Geister, Michael A Hast, Petra Weissenberger
BACKGROUND: Males are increasingly seeking minimally invasive cosmetic procedures such as botulinum toxin injection. However, few studies have specifically examined the efficacy of such procedures among men. OBJECTIVE: To assess the efficacy of incobotulinumtoxinA for treating glabellar frown lines (GFLs) in men. METHODS: Three incobotulinumtoxinA studies were included in post hoc analyses of responder rates: 2 pivotal Phase 3 US registration studies for GFLs (n = 55 males in a pooled analysis) and a European pivotal Phase 3 study for upper facial lines (UFLs; n = 21 males)...
November 2017: Dermatologic Surgery: Official Publication for American Society for Dermatologic Surgery [et Al.]
https://www.readbyqxmd.com/read/29031894/refractory-urgency-urinary-incontinence-treatment-in-women-impact-of-age-on-outcomes-and-complications
#4
Yuko M Komesu, Cindy L Amundsen, Holly E Richter, Stephen W Erickson, Mary F Ackenbom, Uduak U Andy, Vivian W Sung, Michael Albo, W Thomas Gregory, Marie Fidela Paraiso, Dennis Wallace
BACKGROUND: Women with refractory urgency urinary incontinence (ie, unresponsive to behavioral and pharmacological interventions) are treated with onabotulinumtoxinA or sacral neuromodulation. OBJECTIVE: The objective of the study was to compare treatment efficacy and adverse events in women <65 and ≥65 years old treated with onabotulinumtoxinA or sacral neuromodulation. STUDY DESIGN: This study was a planned secondary analysis of a multicenter, randomized trial that enrolled community-dwelling women with refractory urgency urinary incontinence to onabotulinumtoxinA or sacral neuromodulation treatments...
October 12, 2017: American Journal of Obstetrics and Gynecology
https://www.readbyqxmd.com/read/29031769/intra-trigonal-onabotulinum-toxin-a-improves-bladder-symptoms-and-quality-of-life-in-bladder-pain-syndrome-interstitial-cystitis-patients-a-pilot-single-centre-randomized-double-blind-placebo-controlled-trial
#5
R Pinto, D Costa, A Morgado, P Pereira, A Charrua, J Silva, F Cruz
PURPOSE: To compare efficacy and safety of trigonal injections of onabotulinumtoxinA and saline in Bladder Pain Syndrome/Interstitial Cystitis patients. MATERIALS AND METHODS: This phase II study enrolled women with Bladder Pain Syndrome/Interstitial Cystitis >6months and pain ≥4 in 0-10 visual analogue scale, refractory to common treatment. OnabotulinumtoxinA 100U (n=10) or saline (placebo, n=9), were administered as 10 trigonal injections of 1ml. Primary end-point was change from baseline in pain intensity reported at week 12...
October 12, 2017: Journal of Urology
https://www.readbyqxmd.com/read/29024564/videourodynamic-factors-predictive-of-successful-onabotulinumtoxina-urethral-sphincter-injection-for-neurogenic-or-non-neurogenic-detrusor-underactivity
#6
Yuan-Hong Jiang, Jia-Fong Jhang, Sheng-Fu Chen, Hann-Chorng Kuo
OBJECTIVE: The aim of the present study was to analyze treatment outcomes and identify videourodynamic factors predictive of successful urethral onabotulinumtoxinA treatment of neurogenic and non-neurogenic detrusor underactivity (DU). METHODS: Patients with DU refractory to medical treatment were treated with injections totaling 100 U onabotulinumtoxinA into the urethral sphincter. Treatment outcomes were assessed 1 month after treatment using the Global Response Assessment...
October 11, 2017: Lower Urinary Tract Symptoms
https://www.readbyqxmd.com/read/28973094/effect-of-3-commercially-available-botulinum-toxin-neuromodulators-on-facial-synkinesis-a-randomized-clinical-trial
#7
Andrew J Thomas, Michael O Larson, Samuel Braden, Richard B Cannon, P Daniel Ward
Importance: Botulinum toxin neuromodulators are an important treatment for facial synkinesis. Whether a difference in efficacy exists among the 3 different botulinum neuromodulators used in treating this condition remains unknown. Objective: To evaluate the effectiveness of 3 commercially available botulinum toxin neuromodulators in the treatment of facial synkinesis. Design, Setting, and Participants: In this single-blind, 3-arm comparison randomized clinical trial, 28 patients at the Facial Nerve Center, University of Utah, Salt Lake City, were randomized to onabotulinumtoxinA, abobotulinumtoxinA, or incobotulinumtoxinA treatment...
September 28, 2017: JAMA Facial Plastic Surgery
https://www.readbyqxmd.com/read/28953573/real-world-retention-rates-after-intravesical-onabotulinumtoxina-for-idiopathic-overactive-bladder
#8
Daniel Liberman, Olufenwa Milhouse, Marta Johnson-Mitchell, Steven W Siegel
INTRODUCTION: The risk of incomplete bladder evacuation requiring catheterization after intravesical onabotulinumtoxinA (BoNT-A) is well established. However, the rates reported in the literature are highly variable and low overall in clinical trials. We attempt to evaluate the rate of symptomatic acute urinary retention requiring catheterization after initial BoNT-A in a private practice setting of patients with idiopathic overactive bladder. METHODS: We performed a retrospective study from 2010 to 2014 for patients with idiopathic overactive bladder undergoing their first BoNT-A...
September 26, 2017: Female Pelvic Medicine & Reconstructive Surgery
https://www.readbyqxmd.com/read/28919457/patterns-of-botulinum-toxin-treatment-for-spasticity-and-bleeding-complications-in-patients-with-thrombotic-risk
#9
Chetan P Phadke, Vivekanand Thanikachalam, Farooq Ismail, Chris Boulias
The purpose of this study was to assess the prevalence of compartment syndrome or major bleeding episodes and compare compartment syndrome, patient and intervention characteristics in 110 patients with stroke (treated with Warfarin, new oral anticoagulants, antiplatelet, or no anticoagulants) treated for spasticity in deep leg compartment muscles with botulinum toxin injections [onabotulinumtoxinA (n = 77); incobotulinumtoxinA (n = 33)]. We reviewed 674 injection cycles (range 1-25 cycles per patient) and found no cases of compartment syndrome in any patient groups...
November 2017: Toxicon: Official Journal of the International Society on Toxinology
https://www.readbyqxmd.com/read/28905793/re-reduction-of-urgency-severity-is-the-most-important-factor-in-the-subjective-therapeutic-outcome-of-intravesical-onabotulinumtoxina-injection-for-overactive-bladder
#10
https://www.readbyqxmd.com/read/28879545/real-life-use-of-onabotulinumtoxina-for-symptom-relief-in-patients-with-chronic-migraine-repose-study-methodology-and-baseline-data
#11
Brendan Davies, Charly Gaul, Paolo Martelletti, Juan Carlos García-Moncó, Stephanie Brown
BACKGROUND: Migraine is a debilitating neurological disorder that affects 14.1% of the US and 14.7% of the European populations. Chronic migraine (CM) is broadly defined as headache occurring on ≥15 days per month for ≥3 months, and has an estimated worldwide prevalence of 1.4% to 2.2%. OnabotulinumtoxinA is currently approved for the treatment of CM in most European countries, and is the only preventative treatment approved for adults with CM, based on results from the PREEMPT clinical trial programme...
September 6, 2017: Journal of Headache and Pain
https://www.readbyqxmd.com/read/28877510/heart-rate-variability-modifications-induced-by-high-doses-of-incobotulinumtoxina-and-onabotulinumtoxina-in-hemiplegic-chronic-stroke-patients-a-single-blind-randomized-controlled-crossover-pilot-study
#12
Alessio Baricich, Elisa Grana, Stefano Carda, Andrea Santamato, Claudio Molinari, Carlo Cisari, Marco Invernizzi
BACKGROUND: Botulinum toxin type A is a valid and safe treatment for focal spasticity, with documented effects on both sympathetic and parasympathetic systems. Heart rate variability can provide detailed information about the control of the autonomic nervous system on cardiovascular activities. Previous studies in literature showed no significant changes in Heart Rate Variability with doses >600 U of incobotulinumtoxinA in chronic post stroke spastic patients; however, at present time, these results have not been confirmed with doses >600 U of onabotulinumtoxinA...
November 2017: Toxicon: Official Journal of the International Society on Toxinology
https://www.readbyqxmd.com/read/28877509/botulinum-toxin-for-chronic-migraine-clinical-trials-and-technical-aspects
#13
Cristina Tassorelli, Grazia Sances, Micol Avenali, Roberto De Icco, Daniele Martinelli, Vito Bitetto, Giuseppe Nappi, Giorgio Sandrini
OnabotulinumtoxinA has been approved for the prophylaxis of chronic migraine following the demonstration of efficacy in two large controlled trials. Data collected from pragmatic studies in the real-life setting have contributed important additional information useful for the management of this group of extremely disabled and challenging patients. The main findings from these studies are presented and discussed.
September 4, 2017: Toxicon: Official Journal of the International Society on Toxinology
https://www.readbyqxmd.com/read/28877353/adolescence-transitional-care-in-neurogenic-detrusor-overactivity-and-the-use-of-onabotulinumtoxina-a-clinical-algorithm-from-an-italian-consensus-statement
#14
REVIEW
Giovanni Palleschi, Giovanni Mosiello, Valerio Iacovelli, Stefania Musco, Giulio Del Popolo, Antonella Giannantoni, Antonio Carbone, Roberto Carone, Andrea Tubaro, Mario De Gennaro, Antonio Marte, Enrico Finazzi Agrò
AIMS: OnabotulinumtoxinA (onaBNTa) for treating neurogenic detrusor overactivity (NDO) is widely used after its regulatory approval in adults. Although the administration of onaBNTa is still considered off-label in children, data have already been reported on its efficacy and safety. Nowadays, there is a lack of standardized protocols for treatment of NDO with onaBNTa in adolescent patients in their transition from the childhood to the adult age. With the aim to address this issue a consensus panel was obtained...
September 6, 2017: Neurourology and Urodynamics
https://www.readbyqxmd.com/read/28808924/a-critical-evaluation-on-moh-current-treatments
#15
REVIEW
Andrea Negro, Martina Curto, Luana Lionetto, Simona Guerzoni, Luigi Alberto Pini, Paolo Martelletti
Migraine is the most frequent neurological disorder observed in clinical practice characterized by moderate to severe pain attacks associated with neurological, gastrointestinal, and dysautonomic symptoms. Each year, 2.5% of patients with episodic migraine develop chronic migraine (CM). CM is characterized by high frequency of the attacks that may result into chronic intake of abortive medications. Nearly, the 70% of CM patients referring to tertiary head centers show acute pain medications overuse that may lead to the development of medication overuse headache (MOH)...
August 15, 2017: Current Treatment Options in Neurology
https://www.readbyqxmd.com/read/28808734/what-is-the-true-catheterization-rate-after-intravesical-onabotulinumtoxina-injection
#16
Devin N Patel, Juzar Jamnagerwalla, Justin Houman, Jennifer T Anger, Karyn S Eilber
INTRODUCTION AND HYPOTHESIS: A known side effect of intravesical onabotulinumtoxinA (Botox®) injection for overactive bladder (OAB) is urinary retention requiring clean intermittent catheterization (CIC), the fear of which deters patients from choosing this therapy. In clinical practice, patients with an elevated postvoid residual (PVR) are often managed by observation only, providing they do not have subjective complaints or contraindications. We sought to determine the true rate of urinary retention requiring CIC in clinical practice...
August 14, 2017: International Urogynecology Journal
https://www.readbyqxmd.com/read/28808621/von-brunn-s-nests-and-follicular-cystitis-following-intradetrusor-onabotulinumtoxina-injections-for-overactive-bladder
#17
Silpa Nekkanti, Andrew Doering, Debra L Zynger, Andrew F Hundley
A 67-year-old female with refractory OAB was treated with intradetrusor Botox. She subsequently developed multiple papillary bladder lesions with tissue biopsy showing Von Brunn's nests. Von Brunn's nests are benign bladder lesions similar in appearance to a rare urothelial tumor called Nested Variant of Urothelial Carcinoma (NVUC). It is critical that patients with these findings undergo evaluation to rule out the presence of carcinoma. This finding suggests the possibility of a previously unreported adverse reaction in association with intradetrusor Botox...
September 2017: Urology Case Reports
https://www.readbyqxmd.com/read/28805473/the-impact-of-persistence-with-mirabegron-usage-vs-switching-to-onabotulinumtoxina-on-healthcare-costs-and-resource-utilization-in-patients-with-overactive-bladder-in-the-united-states
#18
Daniel Bin Ng, Robert Espinosa, Scott J Johnson, David Walker, Katherine Gooch
AIMS: To compare healthcare costs and resource utilization in patients with overactive bladder (OAB) in the US who switch from mirabegron to onabotulinumtoxinA (onabotA) with those who persist on mirabegron. MATERIALS AND METHODS: A retrospective observational claims analysis of the OptumHealth Administrative Claims database conducted between April 1, 2012 and September 30, 2015 used medical and pharmacy claims to identify patients with at least one OAB diagnosis who switched from mirabegron to onabotA (onabotA group) or persisted on mirabegron for at least 180 days (mirabegron persisters)...
September 4, 2017: Journal of Medical Economics
https://www.readbyqxmd.com/read/28805237/adult-spasticity-international-registry-study-methodology-and-baseline-patient-healthcare-provider-and-caregiver-characteristics
#19
Gerard E Francisco, Daniel S Bandari, Ganesh Bavikatte, Wolfgang H Jost, Aubrey Manack Adams, Joan Largent, Alberto Esquenazi
OBJECTIVE: The main aim of this study was to determine the utilization patterns and effectiveness of onabotulinumtoxinA (Botox®) for treatment of spasticity in clinical practice. DESIGN: An international, multicentre, prospective, observational study at selected sites in North America, Europe, and Asia. PATIENTS: Adult patients with newly diagnosed or established focal spasticity, including those who had previously received treatment with onabotulinum-toxin A...
August 31, 2017: Journal of Rehabilitation Medicine
https://www.readbyqxmd.com/read/28791229/impact-of-bladder-dysfunction-in-the-management-of-post-radical-prostatectomy-stress-urinary-incontinence-a-review
#20
REVIEW
Derek B Hennessey, Nathan Hoag, Johan Gani
Bladder dysfunction is a relatively common urodynamic finding post radical prostatectomy (RP). It can be the sole cause of post prostatectomy incontinence (PPI) or may be found in association with stress urinary incontinence (SUI). The aim of this review is to provide a comprehensive review of the diagnosis and different treatments of post RP bladder dysfunction. A comprehensive literature review using medical search engines was performed. The search included a combination of the following terms, PPI, detrusor overactivity (DO), detrusor underactivity (DU), impaired compliance, anticholinergic, onabotulinumtoxinA (Botox(®)) and sacral neuromodulation (SNM)...
July 2017: Translational Andrology and Urology
keyword
keyword
3072
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"